🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Vinicius Ernani

WinnMed

ORCID: 0000-0002-1865-5801

Also affiliated with Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic in Florida

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial”.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet(2024)10.1016/s0140-6736(24)01756-2
N/A
3.7DataRank · unranked
262 citations

Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +91 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps8598
N/A
0DataRank · unranked
1 citations

Austin W. Goodrich, Nathan R. Foster, Vinicius Ernani, Patrick M. Forde, Liza C. Villaruz +12 more

Clinical outcomes of stage-IV non–small-cell lung cancer in young patients and the impact of tumor markers

Cancer Treatment and Research Communications(2023)10.1016/j.ctarc.2023.100723
N/A
0DataRank · unranked
3 citations

Yalun Li, Vinicius Ernani, Jonathan D’Cunha, Marie‐Christine Aubry, Ping Yang +1 more

Prognostic factors in resected pulmonary carcinoid tumors: A retrospective study with 10 years of follow‑up

Oncology Letters(2023)10.3892/ol.2023.13666
N/A
0DataRank · unranked
2 citations

Vinicius Ernani, Alex C.H. Liu, Steven E. Schild, Dawn E. Jaroszewski, Steven D. Cassivi +9 more

Targeted therapy‑associated cardiotoxicity in patients with stage‑IV lung cancer with or without cardiac comorbidities

Oncology Reports(2024)10.3892/or.2024.8858
N/A
0DataRank · unranked
10 citations

Dong Li, Jason A. Wampfler, Yung‐Hung Luo, Ashok Kumar, Zhong Gu +7 more

Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort

Journal of the American Academy of Dermatology(2024)10.1016/j.jaad.2024.03.029
N/A
0DataRank · unranked
4 citations

Ashok V. Kumar, Zhong Gu, Nikhila Kosuru, Jason A. Wampfler, Pedro Reck dos Santos +6 more

Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity

Heliyon(2024)10.1016/j.heliyon.2024.e28285
N/A
0DataRank · unranked
0 citations

Vinicius Ernani, Dan Liu, Qian Guo, Markay Hopps, Joseph C. Cappelleri +6 more

The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients

BioScience Trends(2025)10.5582/bst.2024.01424
N/A
0DataRank · unranked
0 citations

Collin M. Costello, Zhaoheng Liu, Ashok V. Kumar, Zhong Gu, Nikhila Kosuru +6 more

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.11.006
N/A
0DataRank · unranked
165 citations

Bhakti Dwivedi, Zhengjia Chen, Chao Zhang, Benjamin G. Barwick, Vinicius Ernani +13 more

Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit

JTCVS Open(2025)10.1016/j.xjon.2025.06.005
N/A
0DataRank · unranked
0 citations

Pedro Reck dos Santos, Zhong Gu, Matthew Buras, Juan Farina, Nathan Y. Yu +8 more